13 August 2018
Visiongain’ has launched a new pharma report Brazilian Pharmaceutical Market Outlook 2017-2027: Originator, Generic, OTC, CNS, Cardiovascular, Gastrointestinal, Metabolic, Oncology, Infectious Diseases, Domestic Manufacturers and International Drug Companies
Brazil’s pharmaceutical market is the eighth largest in the world, and is growing at a faster rate than many of the markets in developed countries. Between 2005 and 2013 it experienced double digit growth rates, and the value of the market tripled. Despite current economic challenges, it is set to continue its expansion well into the 2020s, but at lower growth rates. Growth is being driven by a range of factors including a booming generic drugs market, an underlying shift towards chronic diseases, growing affluence in the country, and a government which aims to increase the population’s access to drugs by making numerous technology transfer deals with multinational companies.
The lead analyst of the report commented “While unmet medical needs present an important opportunity in many areas of the Brazilian market, the oncology and diabetes segments are particularly notable. Brazil has the fifth highest number of diabetes patients in the world while cancer has historically gone unaddressed by the healthcare system. SUS is now facilitating easier access to oncology drugs, thus there is an opportunity for growth.
The Brazilian government is pushing towards technology transfer. Technology transfer is likely to galvanise the nation’s domestic pharmaceutical industry as well as saving the SUS money, but it remains to be seen whether indigenous Brazilian companies will fulfil the government’s ambitions by becoming significant originators of pharmaceutical products and technology platforms.”
Leading companies featured in the report include Sanofi/Medley, EMS, Hypermarcas, Novartis, Eurofarma, Aché, Roche, Merck & Co., Pfizer, Takeda.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.